Long-term maintenance of certolizumab pegol safety and efficacy, in combination with methotrexate and as monotherapy, in rheumatoid arthritis patients by Fleischmann, Roy F. et al.
ORIGINAL RESEARCH
Long-Term Maintenance of Certolizumab Pegol Safety
and Efficacy, in Combination with Methotrexate
and as Monotherapy, in Rheumatoid Arthritis Patients
Roy Fleischmann . Ronald F. van Vollenhoven . Jiri Vencovsky´ . Rieke Alten .
Owen Davies . Irina Mountian . Marc de Longueville . David Carter .
Ernest Choy
Received: January 23, 2017
 The Author(s) 2017. This article is an open access publication
ABSTRACT
Introduction: The safety and efficacy of cer-
tolizumab pegol (CZP) 400 mg every 4 weeks
(Q4W) monotherapy (FAST4WARD/
NCT00548834) and in combination with
methotrexate (MTX) (014/NCT00544154) in
active rheumatoid arthritis (RA) has been pub-
lished previously. This report outlines final
long-term outcomes from the open-label
extension (OLE) study (015/NCT00160693),
which enrolled patients from these randomized
controlled trials (RCTs).
Methods: Patients who withdrew from or
completed the 24-week 014/FAST4WARD RCTs
were enrolled and received CZP 400 mg Q4W
with/without MTX. Exposure-adjusted event
rates (ER) per 100 patient-years (PYs) of adverse
events (AEs) and serious AEs (SAEs) were repor-
ted for all patients receiving C1 dose of CZP in
RCTs or OLE (N = 427) between first CZP dose
and up to 24 weeks after last CZP dose or study
withdrawal. Efficacy assessments included clin-
ical (ACR20/50/70 response rates, TJC, SJC) and
patient-reported outcomes (HAQ-DI, PtGADA,
pain, fatigue) to week 304 (5.8 years) in the CZP
intent-to-treat population. SDAI and CDAI
outcomes were analyzed post hoc. Outcomes for
CZP monotherapy and CZP?MTX combina-
tion-therapy were compared.
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Results: Globally, ERs of AEs and SAEs were
408.1 and 25.2 per 100 PY, respectively. Eleven
patients had AEs leading to death (ER 0.6).
Improvements in clinical and patient-reported
outcomes during the 24-week RCTs were
maintained to week 304, and were similar
between all subpopulations.
Conclusions: The longest exposure duration to
date with CZP 400 mg Q4W treatment con-
firmed the safety profile observed in previous
studies. Initial improvements in signs and
symptoms of RA, including PROs, were main-
tained in both CZP monotherapy and
CZP ? MTX combination-therapy patients.
Trial registration: ClinicalTrials.gov identifier,
NCT00160693.
Funding: UCB Pharma.
Keywords: Certolizumab pegol; Monotherapy;
Open-label extension; Rheumatoid arthritis
INTRODUCTION
Rheumatoid arthritis (RA) is a chronic systemic
inflammatory disease associated with signifi-
cant morbidity. RA treatment guidelines rec-
ommend use of methotrexate (MTX) or other
conventional synthetic disease-modifying anti-
rheumatic drugs (csDMARDs) prior to initiation
of anti-tumor necrosis factor (TNF) therapy in
combination with csDMARDs [1, 2]. However,
the use of anti-TNFs as monotherapy is a
potential treatment option for patients with RA
who are intolerant to MTX or for whom MTX
would be inappropriate. Around 30% of RA
patients treated with a biologic receive it as
monotherapy, primarily due to MTX intolera-
bility [3–6].
Certolizumab pegol (CZP) is a PEGylated
Fc-free anti-TNF approved in over 50 countries
for the treatment of RA, ankylosing spondylitis,
axial spondyloarthritis, psoriatic arthritis, and
Crohn’s disease.
The safety and efficacy of CZP in RA, in
combination with MTX and as a monotherapy,
was initially investigated in two phase III ran-
domized controlled trials (RCTs); the Study 014
RCT (NCT00544154) [7] and the FAST4WARD
RCT (NCT00548834) [8]. Patients from these
two 24-week, randomized, double-blind,
placebo-controlled studies entered a single
open-label extension (OLE) study (Study 015;
NCT00160693). These early trials differed from
later CZP clinical trials, such as RAPID 1
(NCT00152386) and RAPID 2 (NCT00175877)
[9, 10], as patients received a CZP dose of 400 mg
every 4 weeks (Q4W) compared to either 200 mg
(with a loading dose of 400 mg every 2 weeks for
the first 4 weeks) or 400 mg every 2 weeks in the
RAPID trials, and patients in FAST4WARD did
not receive concomitant MTX, unlike patients
participating in the RAPID trials.
The primary objective of Study 015 was to
assess the long-term (up to 7 years) safety and
tolerability of CZP 400 mg subcutaneously
Q4W. Secondary objectives were to assess the
sustainability of CZP efficacy for treatment of
the signs and symptoms of RA, including
patient-reported outcomes (PROs), both in
combination with MTX and as a monotherapy.
METHODS
Study Design
Study 015 was a phase III, multi-center,
open-label study of CZP 400 mg Q4W in
patients who initially fulfilled the criteria for
active RA [7, 8], which enrolled patients from
two 24-week, randomized, double-blind,
placebo-controlled studies of CZP: FAST4WARD
and Study 014 (Fig. 1a). FAST4WARD and Study
014 had similar trial designs; however, FAST4-
WARD patients received CZP as a monotherapy
while those in Study 014 received CZP in com-
bination with MTX. Patients could enter the
open-label extension (OLE; Study 015) after
completing the RCT or withdrawing at or after
12 weeks of treatment, provided they had not
withdrawn due to a possible drug-related
adverse event (AE) or non-compliance.
During Study 015, all patients received CZP
400 mg subcutaneously Q4W and were permit-
ted to take csDMARDs, either from study base-
line or at any point, as needed. Visits were
scheduled at OLE entry, week 1, week 4, and
then every 4 weeks thereafter; treatment was
continued until marketing approval in the
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respective countries was obtained (up to
7 years). Patients who attended a completion
visit at site closure due to marketing approval
were considered to have completed the study,
irrespective of treatment duration at site
closure.
This study was conducted in accordance
with the current version of the applicable
regulatory and International Conference on
Harmonisation (ICH)-Good Clinical Practice
(GCP) requirements, the ethical principles that
have their origin in the principles of the Dec-
laration of Helsinki of 1964, and the local laws
of the countries involved. Informed consent
was obtained from all patients for being inclu-
ded in the study.
Fig. 1 Study design. *CZP monotherapy analysis excludes
1 FAST4WARD patient who was receiving MTX at
baseline—patients were excluded from the CZP
monotherapy analysis from the date of concomitant
MTX administration. CZP?MTX group includes all
patients from Study 014 and one patient from FAST4-
WARD study who received MTX at baseline
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Patients
Full inclusion criteria for the FAST4WARD and
Study 014 RCTs have been reported elsewhere
[7, 8]. Briefly, adults with adult-onset active RA
of C6 months’ duration, defined as C9 tender
joints (68 joint count), C9 swollen joints (66
joint count), with one of the following three
criteria: C45-min duration of morning stiffness;
erythrocyte sedimentation rate (ESR; Wester-
gren) C28 mm/h; or C-reactive protein (CRP)
[10 mg/l ([1.0 mg/dl), who had failed C1 prior
csDMARD were eligible for study inclusion.
NSAIDs and oral corticosteroids B10 mg/day
prednisone equivalent were allowed in both
RCTs, if stable for C4 weeks prior to study entry
and maintained throughout the RCT period. All
csDMARDs in FAST4WARD, and csDMARDs
apart from MTX (at least 6 months prior to study
entry, with stable dose of 15–25 mg/week for at
least 8 weeks prior to first study medication dose)
in Study 014, were prohibited. Concomitant
administration of any NSAID, oral corticosteroid,
or csDMARD was permitted throughout Study
015, including addition of MTX for patients
originally enrolled in FAST4WARD.
Safety
The primary objective of Study 015 was to
investigate long-term safety of CZP treatment of
active RA, as measured by adverse events (AEs)
and serious AEs (SAEs).
The safety population in this report included
all patients who receivedC1 dose of CZP in either
the RCT or OLE. All events experienced between
first CZP exposure and 24 weeks after the last
visit/patient withdrawal were included. AEs and
SAEs were assessed at every visit and classified by
system organ class (SOC) and preferred term (PT)
according to the MedDRA dictionary v9.0. AEs
are reported as exposure-adjusted event rates (ER)
per 100 patient-years (PYs), which include mul-
tiple occurrences of an AE in the same patient.
Efficacy Analyses
A secondary objective of the OLE was to inves-
tigate the sustainability of CZP efficacy and
assess the long-term impact of CZP on physical
function in patients who were able to continue
CZP during the OLE.
Efficacy analyses are reported up to week
304 (5.8 years) from the RCT baseline; after
this point, site closure due to marketing
approval reduced overall patient numbers
until they were no longer considered to allow
meaningful analysis of efficacy outcomes. The
efficacy outcomes are reported from the RCT
baseline into the OLE for (1) all patients ran-
domized to receive CZP at RCT baseline (CZP
intent-to-treat [ITT] population), (2) all
patients who received CZP as a monotherapy
at RCT baseline (CZP monotherapy group:
patients were only considered to be part of the
analysis while receiving CZP monotherapy;
once patients initiated concomitant MTX
therapy, their data were excluded from this
analysis) and (3) all patients who received CZP
with MTX at RCT baseline (CZP?MTX group).
Patients who were randomized to placebo at
RCT baseline were not included in these
analyses.
Pre-specified clinical efficacy assessments
investigated in this study were ACR 20/50/70
responder rates [11], tender/painful joint count
(TJC), and swollen joint count (SJC), and Dis-
ease Activity Score (DAS)28-3(CRP). PROs
assessed included the HAQ functional disabil-
ity index (HAQ-DI) [12], patient’s assessment
of arthritis pain [PAAP 0–100 mm visual ana-
logue scale (VAS)], patient’s global assessment
of disease activity (PtGADA, 1–5 Likert scale),
short-form 36 (SF-36) [13], and fatigue assess-
ment (0–10 cm VAS) [14]. The DAS28-3(CRP)
was assessed because PtGADA was not collected
using a 0–100 scale as required for
DAS28-4(CRP) [15]. Post hoc analysis included
Clinical Disease Activity Index (CDAI) change
from RCT baseline, CDAI remission (CDAI
B2.8) [16], Simplified Disease Activity Index
(SDAI) change from RCT baseline and SDAI
remission (SDAI B3.3) [16], which were calcu-
lated using PtGADA and Physician’s Global
Assessments of Disease Activity (PhGADA),
(both collected using 1–5 Likert scales, and
then converted to 10 cm VAS-like outputs as
follows: 1 = 0 cm, 2 = 2.5 cm, 3 = 5 cm,
4 = 7.5 cm, 5 = 10 cm).
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The proportion of patients achieving mini-
mum clinically important difference (MCID)
was also analyzed post hoc and was defined as
HAQ-DI change [0.22 [17, 18], PAAP change
[10 mm [19], PtGADA change [1 on 0–10
VAS (adjusted from 1 to 5 Likert scale), SF-36
physical component summary (PCS) and
mental component summary (MCS) change
[2.5 [20], and fatigue assessment change
[1 cm.
Statistical Analysis
Kaplan–Meier analyses were used to estimate
patient retention in the CZP ITT group and
CZP monotherapy group. The analysis
included a comparison of patients who
withdrew for any reason with those who
withdrew due to AE alone, or lack of efficacy
(including addition of MTX for CZP
monotherapy patients). Patients who with-
draw due to another reason were censored at
the time of withdrawal. Patients who did not
withdraw were censored at their last sched-
uled visit.
Missing data due to withdrawal, missing
assessment, or addition of MTX for
monotherapy patients, were imputed using last
observation carried forward (LOCF) for change
from baseline in DAS28-3(CRP), fatigue assess-
ment, HAQ-DI, PAAP, PtGADA, SJC, TJC, CDAI
and SDAI. For ACR response rates, CDAI
remission, SDAI remission and the proportion
of patients achieving MCID, missing data were
imputed using a combination of non-respon-
der imputation (NRI) and LOCF, which was
used to take into account the reason for with-
drawal during the long follow-up of the OLE:
in the RCT, all missing values were imputed by
LOCF; for patients entering the OLE, LOCF was
used for values missing due to study comple-
tion, missed assessment visit, or withdrawal
not due to AEs, lack of efficacy, or use of MTX
rescue medication in the monotherapy group
during the OLE, with all other missing data
imputed using NRI. Where the table or fig-
ure number is not indicated, data shown are
present in the text only.
RESULTS
Baseline Demographics and Patient
Disposition
Overall, 427 patients received CZP in the RCT or
OLE (safety population). Of these, 235 patients
were originally randomized to CZP in combi-
nation with MTX or as a monotherapy in the
RCTs (CZP ITT group). The other 192 patients
included in the safety population had originally
received placebo across both RCTs before
entering the OLE and receiving CZP. Patients
who received placebo in the RCTs but did not
consent to the OLE were not included in the
safety population. A total of 110 patients were
randomized and received CZP monotherapy in
the FAST4WARD RCT and were therefore ini-
tially included in the CZP monotherapy group.
An additional 125 patients were randomized to
receive CZP in combination with MTX (124
patients from Study 014 and one patient from
FAST4WARD) (Fig. 1). The 192 patients who
were randomized to placebo at RCT baseline
were not included in the CZP monotherapy or
combination groups. Overall, 402 patients
entered the OLE. Patient demographics and
disease characteristics were similar across all
groups at baseline (Table 1).
Kaplan–Meier analysis of withdrawal due to
lack of efficacy, adverse events, or not consent-
ing to enter the OLE estimated a patient reten-
tion rate of 50.4% in CZP ITT patients up to
week 364 (*7 years from RCT baseline; Fig-
ure S1). The Kaplan–Meier analysis of the CZP
monotherapy group treated addition of MTX as
a withdrawal due to lack of efficacy event for
these patients, and estimated a patient reten-
tion rate of 44.8% at week 355 (week of last visit
for monotherapy group). Accounting for
patient withdrawal due to lack of efficacy alone
and AEs alone provided estimated retention
rates of 79.0% and 70.2% at week 364 for CZP
ITT patients, and 65.4% and 76.1% at week 355
for patients receiving CZP monotherapy (Fig-
ure S1C and S1D).
Patients were enrolled in the OLE between
March 2003 and June 2004. As study sites were
closed when CZP received marketing
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authorization (including FDA and EMA
approval in 2009), a total of 67 patients
remained in the study to week 364 of treatment
(Fig. 1b). Of the patients who initiated CZP
monotherapy, 18 subsequently received con-
comitant MTX in the RCT or OLE. The most
common reason for withdrawal from the OLE
was due to an AE [97 patients (24.1% of all
patients entering the OLE)], followed by con-
sent withdrawn and lack of efficacy [54 (13.4%)
and 30 (7.5%), respectively] (Fig. 1b).
Safety
The longest CZP treatment duration in the
complete safety population was 394 weeks
(7.6 years), with a mean exposure of 213 weeks
(4.1 years) and median exposure of 256 weeks
(4.9 years). Of the patients that entered the
OLE, 33 (8.3%) received concomitant corticos-
teroids and 328 (81.6%) received concomitant
glucocorticoids during Study 015. Due to limi-
tations in reporting, it was not possible to
accurately track changes in the dosage of con-
comitant medication. The ER of SAEs was 25.2
per 100 PY, with the most frequent SAEs
observed in the SOC categories infections/in-
festations, cardiac disorders and neoplasms
benign, malignant and unspecified (incl. cysts
and polyps) (ER = 4.5, 2.2, and 1.6 per 100 PY,
respectively, Table 2).
The ERs per 100 patient-years in the safety
population for serious infections (4.5) and AEs
leading to withdrawal (7.8) were similar to pre-
viously reported rates for CZP therapy (Table 2).
In the safety population, 11 AEs leading to
death were reported (ER: 0.6 per 100 PY): seven
Table 1 Patient characteristics at RCT baseline
Safety population
(N5 427)
CZP ITT group
(N5 235)
CZP1MTX group
(n5 125)
CZP monotherapy
group (n5 110)
Age (years), mean (SD) 53.4 (12.1) 52.3 (12.5) 52.5 (12.4) 52.1 (12.8)
Gender (% female) 75.9% 75.7% 73.6% 78.2%
Disease duration (years), mean (SD) 9.4 (8.1) 9.0 (7.8) 9.6 (7.9) 8.4 (7.7)
TJC (0–68), mean (SD) – 29.3 (12.7) 29.2 (12.0) 29.4 (13.5)
SJC (0–66), mean (SD) – 22.1 (9.7) 23.1 (9.4) 21.0 (9.9)
PAAP (0–100 VAS), mean (SD) 57.1 (20.9) 57.5 (21.3) 56.8 (20.8) 58.2 (22.0)
PtGADA (1–5 Likert scale),
mean (SD)
3.3 (0.7) 3.3 (0.7) 3.3 (0.7) 3.3 (0.8)
HAQ-DI, mean (SD) 1.4 (0.6) 1.4 (0.6) 1.4 (0.6) 1.4 (0.6)
SF-36 PCS, mean (SD) – 30.2 (7.5) 29.8 (7.7) 30.7 (7.3)
SF-36 MCS, mean (SD) – 44.1 (12.7) 44.0 (12.8) 44.3 (12.6)
DAS28-3(CRP), median 5.8 5.8 5.8 5.7
CRP (mg/L), mean (SD) 21.1 (26.3) 21.0 (24.8) 18.9 (21.8) 23.3 (27.7)
SDAI, mean (SD) – 46.4 (13.4) 47.2 (13.3) 45.5 (14.1)
CDAI, mean (SD) – 44.3 (12.8) 45.3 (12.7) 43.2 (12.8)
CRP C-reactive protein, DAS Disease Activity Score, HAQ-DI Health Assessment Questionnaire-Disability Index, PAAP
patient’s assessment of global arthritis pain, PtGADA patient’s global assessment of disease activity, SD standard deviation,
SJC swollen joint count, SF-36 MCS short form-36 mental component summary, SF-36 PCS short form-36 physical
component summary, TJC tender joint count
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cardiovascular events, two infections, one
injury and one malignancy. The ER of AEs was
highest during the first 3 months of treatment,
which is a trend that has previously been
reported. There was no increase in the rates of
infections, cardiac disorders or malignancies
over time (Table S1).
Clinical Efficacy
Rapid improvements in clinical disease activity
reported in CZP ITT patients during the RCTs,
including both CZP?MTX and CZP monother-
apy group, were maintained over 304 weeks
(Fig. 2). In the CZP ITT patient group (both
combination and monotherapy patients)
ACR20 and ACR50 responses were maintained
between week 24 and week 304 (ACR20/50
52.3%/23.0% at week 24 and 42.6%/20.9% at
week 304), whereas the ACR70 response rate
continued to improve from 3.4% at week 24 to
6.4% at week 32 and was then maintained to
week 304 (6.4%) (Fig. 2a). Similar results were
reported in the CZP?MTX group (ACR20/50/70
51.2%/18.4%/0% at week 24 and 40.0%/16.0%/
4.0% at week 304) and CZP monotherapy group
(ACR20/50/70 52.7%/27.3%/7.3% at week 24
and 37.3%/22.7%/7.3% at week 304). As
expected, observed case response rates for both
combination and monotherapy patients in the
CZP ITT group continued to improve through-
out the OLE, with ACR20/50/70 rates at 49.5%/
21.4%/2.9% (n = 210) at week 24, 72.3%/
34.0%/11.3% (n = 141) at week 160 and 74.3%/
37.1%/11.4% (n = 105) at week 304. Improve-
ments were reported in TJC and SJC from
baseline to week 24 OLE entry in CZP ITT and
both treatment sub-groups. These decreases in
TJC and SJC were maintained long-term to week
304 in all groups (Fig. 2d). The CZP ITT group
observed case values were 15.7 and 10.7 at week
24 (n = 210), 7.4 and 4.6 at week 160 (n = 139),
and 5.7 and 3.2 at week 304 (n = 105) for TJC
and SJC scores, respectively.
In the CZP ITT, CZP?MTX and CZP
monotherapy groups, the post hoc analysis of
change from baseline in SDAI at week 24
(-23.6, -24.6 and -22.8, respectively)
increased to week 304 (-26.9, -28.1 and
-24.2). The post hoc analysis of change from
baseline in CDAI was similar (week 24: -22.6,
-23.8 and -21.5, week 304: -25.9, -27.8 and
-22.8, in CZP ITT, CZP?MTX and CZP
monotherapy groups, respectively). Absolute
scores for CDAI and SDAI are presented in
Fig. 2. At week 24, 3.4% of CZP ITT patients
(3.3% of CZP?MTX and 3.6% of CZP
Table 2 Summary of adverse events (AEs) in all patients
treated with CZP in the RCTs or OLE (safety population)
Event
Primary system organ class
High level term
Preferred Term
Event rate per 100 PY
Safety population
(N5 427)
AEs leading to death 0.6
AEs leading to withdrawal 7.8
Infections and infestations 2.3
Any AEa 408.1
Infections and infestations 112.2
Tuberculosis 0.2
Candida infection (including
topical)
1.1
Herpes viral infections 5.6
Herpes simplex 4.0
Herpes zoster 1.6
Injection and infusion site
reactions
3.6
Injection site reaction 1.1
Injection site pain 0.5
Any serious AE (SAEs) 25.2
Infections and infestations 4.5
Cardiac disorders 2.2
Neoplasmsb 1.6
Safety population included all patients who received CZP
in either the RCT or OLE. MedDRA version 9.0
a 43.6% of AEs for the safety population were classed as
severe in intensity
b Neoplasms could be benign, malignant, or unspeciﬁed
(includes cysts and polyps)
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monotherapy patients) were in SDAI remission,
which rose to 7.7% (5.6 and 8.2%) by week 304.
Similarly, CDAI remission was reported in 4.7,
4.0, and 5.5% of CZP ITT, CZP?MTX and CZP
monotherapy patients at week 24, with remis-
sion rates increasing to week 304 (9.4, 8.0, and
9.1%).
Patient-Reported Outcomes
Rapid improvements in PROs observed during
the RCT were maintained to week 304 in the
CZP ITT group, including both patients receiv-
ing CZP ? MTX and CZP monotherapy (Fig. 3).
Proportions of patients reporting a MCID in
HAQ-DI decreased from week 24 to week 304
(Fig. 4), although week 24 HAQ-DI mean scores
were maintained to week 304 in the CZP ITT
population (1.04–1.07) [including CZP?MTX
(1.10–1.12) and CZP monotherapy (0.96–1.02)
groups] (Fig. 3b). Observed case HAQ-DI values
decreased between week 24 and week 304 in
CZP ITT patients [week 24: 1.09 (n = 208), week
304: 0.83 (n = 105)].
The proportion of patients reporting MCID
in pain (PAAP), fatigue, PtGADA, and SF-36 PCS
and MCS decreased between week 24 and week
304 (Fig. 4). Observed values for PAAP and
PtGADA in CZP ITT patients were 39.0 and 2.7
(n = 210) at week 24, and 27.7 and 2.3 (n = 105)
at week 304, respectively.
DISCUSSION
This data represents the longest reported trial
duration for CZP therapy to date, and demon-
strates the long-term safety of CZP 400 mg Q4W
maintenance dose over approximately 7.6 years
Fig. 2 Clinical efﬁcacy outcomes for CZP ITT patients
(N = 235), and the CZP monotherapy (n = 110) and
CZP?MTX (n = 125) sub-populations: a ACR20/50/70
(NRI/LOCF); b mean SDAI (absolute values, LOCF);
c Mean CDAI (absolute values, LOCF); d mean tender
joint count (TJC; absolute values, LOCF) and swollen
joint count (SJC; absolute values, LOCF)
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and efficacy over just under 6 years, both in
combination with MTX and as a monotherapy,
which have not previously been published.
No new safety signals were observed over the
course of the 7-year treatment period, with AE
ERs comparable to other long-term anti-TNF
studies [21–24]. AEs were consistent with other
long-term evaluations of CZP in combination
with MTX given as a 200 mg dose every 2 weeks
(Q2W) [25–27]. Kaplan–Meier estimates of
patient retention were high in both the CZP ITT
and CZP monotherapy groups (up to 50% at
7 years), which is similar to retention rates
described for longer-term trials of other
anti-TNFs [22–24]. Although the Kaplan–Meier
analyses of patient retention reported lower
retention rates in the CZP monotherapy group
compared to the ITT population, this was pri-
marily driven by the use of MTX addition as a
withdrawal due to lack of efficacy event in the
CZP monotherapy group analyses. Lack of effi-
cacy was given as the reason for withdrawal in
8.6% of ITT and 9.3% of CZP monotherapy
patients.
Efficacy was sustained over the longer term
(5.8 years) in these patients, both in terms of
clinical measures and PROs. Improvements in
clinical measures (ACR20/50/70, TJC, SJC, SDAI,
and CDAI) achieved during the 24-week RCTs
were maintained to week 304. Maintenance of
response was similar between the CZP ITT,
CZP?MTX, and CZP monotherapy groups in
virtually all measures, especially depth of
response as measured by ACR50 and ACR70
response rates.
PROs measure aspects of disease that cannot
be easily assessed by physicians, as they quan-
tify reports of patient health provided directly
Fig. 3 Clinical and patient-reported outcomes for CZP
ITT patients (N = 235), and the CZP monotherapy
(n = 110) and CZP ?MTX (n = 125) sub-populations:
a HAQ-DI (absolute values, LOCF); b pain (PAAP;
absolute values, LOCF); c fatigue (absolute values, LOCF);
d PtGADA (absolute values, LOCF)
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by the patient. Assessing PROs is therefore
important for measuring the impact of the dis-
ease from the patient perspective [28–30]. Sus-
tained efficacy in terms of PRO measures
(HAQ-DI, PtGADA, pain, and fatigue) was
observed to week 304 in CZP ITT and both
CZP?MTX and CZP monotherapy groups, and
was consistent with reports of sustained
CZP?MTX efficacy in the RAPID 1 and 2 OLEs
[25, 26].
The consistency between the long-term
safety profile, patient retention and sustain-
ability of response of CZP 400 mg Q4W reported
in the present study and CZP 200 mg Q2W with
MTX reported in the RAPID 1 and RAPID 2 OLEs
[25, 26] support the use of the CZP 400 mg Q4W
maintenance dose in clinical practice. This
dosing schedule may be more convenient for
some patients, and therefore has the potential
to ease the burden of treatment for RA patients.
A number of limitations of the study design,
previously described for the RCTs [7, 8], also
apply to the present report of Study 015. The
1–5 Likert scale, which is much less sensitive to
change than continuous VAS assessments as
used in the RAPID trials, was used to collect the
PtGADA and PhGADA in both the RCT and OLE
studies. In addition, a combination of low ini-
tial CRP levels and the assay sensitivity resulted
in a potential floor effect in terms of CRP level
[7]. Therefore, three of the seven core ACR
components had a limited sensitivity to change,
and may have impacted the absolute response
size observed. This limitation in data collection
also impacted the post hoc analyses of CDAI
and SDAI, as PtGADA and PhGADA needed to
be converted to VAS-like outputs in order to
calculate CDAI/SDAI change from baseline and
remission rates. Therefore, TJC and SJC scores
are reported in order to provide a more com-
parable measure of efficacy across studies. The
safety population initially comprised 427
patients, of whom only 167 completed the OLE,
which raises the possibility of selection bias in
the safety analyses. Additionally, the OLE study
design has limitations, such as the open-label
nature of the study and the inherent survival
bias, and the lack of a placebo control. However,
given the ethical and regulatory restrictions for
long-term placebo-controlled trials in rheuma-
tology, OLE data are still valuable in informing
long-term treatment choices. Comparisons
between the CZP monotherapy and CZP ITT
population were also limited in this study due
Fig. 4 Proportion of CZP ITT and CZP monotherapy
patients achieving minimal clinically important difference
(MCID) in HAQ-DI, pain (PAAP), fatigue, patient global
assessment of disease activity (PtGADA), and SF-36
physical (PCS) and mental (MCS) components summary
(% of patients, NRI/LOCF). Week 292 data presented
where week 304 unavailable. Patients initially assigned to
the CZP monotherapy group who achieved an MCID but
also received MTX rescue medication prior to each visit
were still included in the CZP ITT analysis, but excluded
from the CZP monotherapy analysis
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to the lower treatment duration in the CZP
monotherapy group (mean 3.4 vs. 4.1 years).
CONCLUSIONS
This study has demonstrated that CZP 400 mg
Q4W had an acceptable safety profile over the
long term (up to 7 years), and was also effective
in maintaining initial improvements in signs
and symptoms of RA, physical function, pain
and fatigue over the longer term. These data
support and build on previously published
long-term data to 5 years for RAPID 1 and
RAPID 2 OLEs [25, 26].
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